These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

883 related articles for article (PubMed ID: 32439271)

  • 1. Overall survival and PD-L1 expression in patients with recurrent or metastatic head and neck cancer treated with nivolumab.
    Okamoto I; Sato H; Tsukahara K
    Auris Nasus Larynx; 2020 Aug; 47(4):676-686. PubMed ID: 32439271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.
    Zandberg DP; Algazi AP; Jimeno A; Good JS; Fayette J; Bouganim N; Ready NE; Clement PM; Even C; Jang RW; Wong S; Keilholz U; Gilbert J; Fenton M; Braña I; Henry S; Remenar E; Papai Z; Siu LL; Jarkowski A; Armstrong JM; Asubonteng K; Fan J; Melillo G; Mesía R
    Eur J Cancer; 2019 Jan; 107():142-152. PubMed ID: 30576970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients.
    Li L; Chen L; Yan L; Guo Y; Li F; Fan M; Lan M; Lai X; Zhou J; Huang Y; Xu P; Lang J; Feng M
    Radiat Oncol; 2023 Jul; 18(1):109. PubMed ID: 37403098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-L1 Expression and Survival Rates Using TPS and CPS for Nivolumab-treated Head-and-Neck Cancer.
    Ito T; Okamoto I; Tokashiki K; Sato H; Okada T; Yamashita G; Nagao T; Hirai H; Saigusa N; Tsukahara K
    Anticancer Res; 2022 Mar; 42(3):1547-1554. PubMed ID: 35220251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Age-based efficacy and safety of nivolumab for recurrent or metastatic head and neck squamous cell carcinoma: A multicenter retrospective study.
    Kondo T; Okamoto I; Sato H; Koyama N; Fushimi C; Okada T; Masubuchi T; Miura K; Matsuki T; Yamashita T; Omura G; Takahashi H; Tsukahara K
    Asia Pac J Clin Oncol; 2020 Dec; 16(6):340-347. PubMed ID: 32573033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic role of programmed cell death ligand-1 expression in head and neck cancer treated with programmed cell death protein-1/programmed cell death ligand-1 inhibitors: A meta-analysis based on clinical trials.
    Huang Z; Zheng S; Ding S; Wei Y; Chen C; Liu X; Li H; Xia Y
    J Cancer Res Ther; 2021 Jul; 17(3):676-687. PubMed ID: 34269299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.
    Ferris RL; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Harrington KJ; Kasper S; Vokes EE; Even C; Worden F; Saba NF; Docampo LCI; Haddad R; Rordorf T; Kiyota N; Tahara M; Lynch M; Jayaprakash V; Li L; Gillison ML
    Oral Oncol; 2018 Jun; 81():45-51. PubMed ID: 29884413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea.
    Kim H; Kwon M; Kim B; Jung HA; Sun JM; Lee SH; Park K; Ahn MJ
    BMC Cancer; 2020 Aug; 20(1):727. PubMed ID: 32758163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05.
    Park JH; You GL; Ahn MJ; Kim SW; Hong MH; Han JY; Ock CY; Lee JS; Oh IJ; Lee SY; Kim CH; Min YJ; Choi YH; Ryu JS; Park SH; Ahn HK; Shim BY; Lee KH; Lee SY; Kim JS; Yi J; Choi SK; An H; Kang JH
    J Cancer Res Clin Oncol; 2021 Aug; 147(8):2459-2469. PubMed ID: 33523301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Pai SI; Cohen EEW; Lin D; Fountzilas G; Kim ES; Mehlhorn H; Baste N; Clayburgh D; Lipworth L; Resteghini C; Shara N; Fujii T; Zhang J; Stokes M; Wang H; Twumasi-Ankrah P; Wildsmith S; Khaliq A; Melillo G; Shire N
    J Transl Med; 2019 Dec; 17(1):429. PubMed ID: 31878938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12.
    Lee YG; Chang H; Keam B; Chun SH; Park J; Park KU; Shin SH; An HJ; Lee KE; Lee KW; Kim HR; Kim SB; Ahn MJ; Hwang IG
    Cancer Res Treat; 2021 Jul; 53(3):671-677. PubMed ID: 33285051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-center prospective study on the efficacy of nivolumab against platinum-sensitive recurrent or metastatic head and neck squamous cell carcinoma.
    Okamoto I; Tsukahara K; Sato H
    Sci Rep; 2022 Feb; 12(1):2025. PubMed ID: 35132165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
    Saâda-Bouzid E; Defaucheux C; Karabajakian A; Coloma VP; Servois V; Paoletti X; Even C; Fayette J; Guigay J; Loirat D; Peyrade F; Alt M; Gal J; Le Tourneau C
    Ann Oncol; 2017 Jul; 28(7):1605-1611. PubMed ID: 28419181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined approach for predicting the efficacy of nivolumab in head and neck carcinoma by tissue and soluble expressions of PD-L1 and PD-L2.
    Sato R; Komatsuda H; Inoue T; Wakisaka R; Kono M; Yamaki H; Ohara K; Kumai T; Kishibe K; Hayashi T; Takahara M
    Head Neck; 2024 Sep; 46(9):2233-2243. PubMed ID: 38665131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
    Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
    Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
    [No Abstract]   [Full Text] [Related]  

  • 16. Association of autoimmunity with survival in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab.
    Economopoulou P; Kotsantis I; Papaxoinis G; Gavrielatou N; Anastasiou M; Pantazopoulos A; Kavourakis G; Gkolfinopoulos S; Panayiotides I; Delides A; Psyrri A
    Oral Oncol; 2020 Dec; 111():105013. PubMed ID: 32977184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use.
    Ferris RL; Licitra L; Fayette J; Even C; Blumenschein G; Harrington KJ; Guigay J; Vokes EE; Saba NF; Haddad R; Ramkumar S; Russell J; Brossart P; Tahara M; Colevas AD; Concha-Benavente F; Lynch M; Li L; Gillison ML
    Clin Cancer Res; 2019 Sep; 25(17):5221-5230. PubMed ID: 31239321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of programmed death-ligand 1 in predicting the treatment outcome of salvage chemotherapy after nivolumab in recurrent/metastatic head and neck squamous cell carcinoma.
    Ueki Y; Takahashi T; Ota H; Shodo R; Yamazaki K; Horii A
    Head Neck; 2020 Nov; 42(11):3275-3281. PubMed ID: 32671898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Nivolumab and Pembrolizumab in Platinum-sensitive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
    Yamashita G; Okamoto I; Ito T; Tokashiki K; Okada T; Tsukahara K
    Anticancer Res; 2023 Aug; 43(8):3679-3683. PubMed ID: 37500154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proton pump inhibitors and antibiotics adversely effect the efficacy of nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
    Wada A; Enokida T; Okano S; Sato M; Tanaka H; Ueda Y; Fujisawa T; Takeshita N; Tanaka N; Tahara M
    Eur J Cancer; 2023 May; 184():30-38. PubMed ID: 36898232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.